Hai Li1, Xin Zhou2, Jun Zhu3, Wenfang Cheng4, Wei Zhu2, Yongqian Shu2, Ping Liu2. 1. Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 2. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 3. Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China. 4. Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract
BACKGROUND: MiR-4728 was recently identified to be related with HER2 in several cell lines and limited tissue samples. OBJECTIVE: To investigate whether miR-4728 could predict HER2 status in a larger cohort. METHODS: The expression of miR-4728-3p and miR-4728-5p was identified in breast cancer (BC) and gastric cancer (GC) tissues with different HER2 status using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). An additional 22 plasma samples was investigated to explore the potential application of miR-4728 as a non-invasive biomarker in predicting HER2 status. RESULTS: MiR-4728-3p and miR-4728-5p were significantly up-regulated in HER2-positive patients compared with HER2-negative patients. Compared with the expression in adjacent normal tissues, miR-4728-3p and miR-4728-5p were both elevated in HER2-negative and HER2-positive GC tissues but only miR-4728-3p in HER2-positive BC tissues. Further analyses revealed that miR-4728-3p had greater ability than miR-4728-5p in discriminating subgroups with different intensity of HER2 staining in both BC and GC patients. In addition, miR-4728-3p but not miR-4728-5p was significantly up-regulated in plasma of BC patients with positive HER2. CONCLUSIONS: MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
BACKGROUND:MiR-4728 was recently identified to be related with HER2 in several cell lines and limited tissue samples. OBJECTIVE: To investigate whether miR-4728 could predict HER2 status in a larger cohort. METHODS: The expression of miR-4728-3p and miR-4728-5p was identified in breast cancer (BC) and gastric cancer (GC) tissues with different HER2 status using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). An additional 22 plasma samples was investigated to explore the potential application of miR-4728 as a non-invasive biomarker in predicting HER2 status. RESULTS:MiR-4728-3p and miR-4728-5p were significantly up-regulated in HER2-positive patients compared with HER2-negative patients. Compared with the expression in adjacent normal tissues, miR-4728-3p and miR-4728-5p were both elevated in HER2-negative and HER2-positive GC tissues but only miR-4728-3p in HER2-positive BC tissues. Further analyses revealed that miR-4728-3p had greater ability than miR-4728-5p in discriminating subgroups with different intensity of HER2 staining in both BC and GC patients. In addition, miR-4728-3p but not miR-4728-5p was significantly up-regulated in plasma of BC patients with positive HER2. CONCLUSIONS:MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
Authors: Joel Pekow; Alan L Hutchison; Katherine Meckel; Kymberly Harrington; Zifeng Deng; Nitya Talasila; David T Rubin; Stephen B Hanauer; Roger Hurst; Konstantin Umanskiy; Alessandro Fichera; John Hart; Aaron R Dinner; Marc Bissonnette Journal: Inflamm Bowel Dis Date: 2017-08 Impact factor: 5.325
Authors: Inga Newie; Rolf Søkilde; Helena Persson; Thiago Jacomasso; Andrej Gorbatenko; Åke Borg; Michiel de Hoon; Stine F Pedersen; Carlos Rovira Journal: Sci Rep Date: 2016-10-18 Impact factor: 4.379